In short, yes it could. The recent Panorama programme focussed on people with relapsing MS, but many people are asking whether people with progressive MS could be helped too.
In this blog, Jane from the Information Team looks at some of the research so far, what’s possible now and where we might expect to see further progress in the future.
Does AHSCT work for progressive MS?
Sometimes it does although it seems to work well only if your MS has a mix of progression with inflammatory activity.
AHSCT (also known as ASCT or HSCT) uses your own haematopoietic stem cells collected from your blood. They are put back into your blood stream after your immune system has been largely wiped out with chemotherapy drugs. The idea is that the immune system is rebuilt in a way that slows down or stops MS disease activity.
AHSCT has been tested more than any other kind of stem cell therapy for MS. It has been tried in people with all types of MS but works better for some than others. Those who are helped the most are people who have inflammation as part of their MS. This generally means having active lesions on MRI scans or continuing relapses despite treatment with disease modifying drugs. This group includes many people with relapsing MS but also a small number with progressive forms of MS. This is an important point – whether AHSCT is likely to work is about whether there’s ongoing inflammation, or not, rather than the type of MS. Having said that, I need to emphasise that not many people with progressive MS have inflammation so the numbers who might benefit from AHSCT, in its current form, are going to be small.
ACTiMuS – a clinical trial for progressive MS
If you don’t have active inflammation and damage has already been done, another approach will be needed. There are research teams around the world developing different stem cell therapies and the outlook seems good. I’ll talk about one example.
The ACTiMuS clinical trial, part funded by the MS Trust, is testing a kind of stem cell therapy for people with progressive MS. It uses a type of stem cells called mesenchymal stem cells which are harvested from the person’s own hip bone marrow then reintroduced to their blood stream. The idea is that the stem cells will work to protect nerve cells from damage and encourage the repair of existing damage. This approach to cell therapy does not need aggressive chemotherapy and so has far fewer risks than AHSCT. A pilot study to check the safety of the procedure went well so the ACTiMuS trial is now testing this approach in more people with MS (this trial is already in progress and the researchers are not looking for more participants).
What does the future look like?
I’ve only looked at a couple of examples in this blog but there is every reason to hope that stem cell therapy will become more widely available, including for people with progressive MS.
The MS Trust is committed to making this happen. We are funding a group in London to conduct the first ever audit of a real-world UK MS stem cell service run outside a clinical trial. From this audit, the researchers hope to understand how people with MS can be assessed and selected for stem cell treatment, and what is needed to develop safe, high quality services for the future. That way, the right people should be offered AHSCT and those who won’t benefit will be spared a lengthy, sometimes painful and relatively risky procedure. You can help to fund this important work by making a donation.
The MS Trust is one of the funders of the ACTiMuS clinical trial which is focussed on developing an effective stem cell therapy for people with progressive MS. This is part of the worldwide commitment by MS researchers to develop stem cell therapies that could work for people with progressive MS.
We will let you know the results of research into stem cell therapy through our website, our email alerts and our newsletter, Open Door. You can keep in touch with the MS Trust andhelp us to continue our work supporting everyone living with MS.
Ofatumumab (Kesimpta) approved for relapsing MS in England and Wales
20 Apr 2021 - 00:00
The MS Trust is delighted that ofatumumab (Kesimpta) has been approved by NICE for people with active relapsing remitting multiple sclerosis.
Under-the-skin injection of Tysabri gets licence in UK and Ireland
16 Apr 2021 - 00:00
Under-the-skin (subcutaneous) injection of Tysabri (natalizumab) has been approved for UK and Ireland.
Ofatumumab (Kesimpta) gets UK licence for relapsing remitting MS
14 Apr 2021 - 00:00
The MHRA has granted marketing authorisation for ofatumumab (Kesimpta) for active relapsing remitting MS.
"Starting a podcast in lockdown helped us take ownership of the situation"
23 Apr 2021 - 00:00
Comedian, Jeanette and Poet, Lytisha, talk about how creating their own podcast, about life with MS, led to lots of laughs, feelings of empowerment and a sense of community during lockdown.
Twelve year old Lacey hasn't been able to hug her dad for a year
23 Apr 2021 - 00:00
Before lockdown Lacey visited her dad every other weekend, but Covid restrictions have meant she’s not been able to visit her dad in his care home and give him a hug since March 2020.
'This is my normal now. I rather like it.' Living with PPMS in lockdown
23 Apr 2021 - 00:00
John Peters tells us how his working life changed during lockdown and how he’ll be quite happy not to go back to ‘normal’.